News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
36,960 Results
Type
Article (1743)
Company Profile (3)
Press Release (35214)
Section
Business (15608)
Career Advice (80)
Deals (2754)
Drug Delivery (3)
Drug Development (3880)
Employer Resources (3)
FDA (787)
Job Trends (819)
News (22170)
Policy (1208)
Tag
Academia (50)
Adcomms (1)
Allergies (4)
Alliances (1527)
ALS (6)
Alzheimer's disease (58)
Antibody-drug conjugate (ADC) (2)
Approvals (802)
Artificial intelligence (13)
Bankruptcy (16)
Best Places to Work (680)
Biosimilars (4)
Biotechnology (3)
Bladder cancer (4)
Breast cancer (30)
Cancer (152)
Cardiovascular disease (13)
Career advice (71)
Career pathing (1)
CAR-T (2)
Cell therapy (8)
Cervical cancer (2)
Clinical research (3497)
Collaboration (25)
Compensation (25)
COVID-19 (64)
C-suite (3)
Cystic fibrosis (5)
Data (170)
Depression (2)
Diabetes (15)
Diagnostics (390)
Digital health (2)
Diversity, equity & inclusion (1)
Drug discovery (5)
Drug pricing (2)
Drug shortages (3)
Duchenne muscular dystrophy (6)
Earnings (13353)
Employer resources (2)
Events (3643)
Executive appointments (15)
FDA (897)
Funding (27)
Gene editing (3)
Generative AI (1)
Gene therapy (11)
GLP-1 (41)
Government (107)
Guidances (47)
Healthcare (1040)
Immunology and inflammation (2)
Indications (2)
Infectious disease (71)
Inflammatory bowel disease (11)
Influenza (1)
Intellectual property (4)
Interviews (20)
IPO (1905)
Job creations (191)
Job search strategy (42)
Labor market (6)
Layoffs (26)
Legal (251)
Liver cancer (2)
Lung cancer (29)
Lymphoma (24)
Manufacturing (15)
MASH (2)
Medical device (843)
Medtech (843)
Mergers & acquisitions (874)
Metabolic disorders (42)
Multiple sclerosis (5)
NASH (1)
Neurodegenerative disease (5)
Neuropsychiatric disorders (1)
Neuroscience (86)
NextGen: Class of 2025 (229)
Non-profit (123)
Obesity (29)
Opinion (4)
Ovarian cancer (6)
Pain (5)
Pancreatic cancer (9)
Parkinson's disease (4)
Partnered (1)
Patents (8)
Patient recruitment (1)
Peanut (4)
People (1100)
Phase I (808)
Phase II (1456)
Phase III (1409)
Pipeline (265)
Postmarket research (178)
Preclinical (250)
Press Release (1)
Prostate cancer (1)
Psychedelics (1)
Radiopharmaceuticals (13)
Rare diseases (20)
Real estate (204)
Recruiting (2)
Regulatory (950)
Reports (4)
Research institute (53)
Resumes & cover letters (20)
RSV (2)
Schizophrenia (8)
Series A (4)
Service/supplier (1)
Sickle cell disease (3)
Spinal muscular atrophy (15)
Startups (124)
Stomach cancer (1)
Supply chain (2)
Vaccines (14)
Venture capitalists (2)
Weight loss (15)
Women's health (1)
Date
Last 7 days (106)
Last 30 days (225)
Last 365 days (2264)
2025 (825)
2024 (2553)
2023 (2683)
2022 (3033)
2021 (3030)
2020 (2816)
2019 (2109)
2018 (1733)
2017 (1544)
2016 (1167)
2015 (1394)
2014 (990)
2013 (690)
2012 (729)
2011 (844)
2010 (6529)
Location
Africa (29)
Alabama (3)
Arizona (9)
Asia (2061)
Australia (223)
California (441)
Canada (120)
China (30)
Colorado (21)
Connecticut (23)
Delaware (38)
Europe (4635)
Florida (57)
Georgia (17)
Idaho (4)
Illinois (44)
India (3)
Indiana (42)
Japan (16)
Kansas (4)
Kentucky (2)
Louisiana (3)
Maine (5)
Maryland (53)
Massachusetts (276)
Michigan (17)
Minnesota (24)
Missouri (1)
Montana (2)
Nebraska (1)
Nevada (1)
New Hampshire (9)
New Jersey (150)
New Mexico (2)
New York (156)
North Carolina (57)
Northern California (227)
Ohio (14)
Oregon (2)
Pennsylvania (116)
Rhode Island (1)
South America (60)
South Carolina (2)
Southern California (145)
Tennessee (4)
Texas (43)
United States (1669)
Utah (21)
Virginia (3)
Washington D.C. (2)
Washington State (34)
Wisconsin (3)
36,960 Results for "125".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FDA Approves New, Low-Dose Chlorthalidone for the Treatment of Hypertension in Adults: HemiClor™ (12.5 mg chlorthalidone)
May 7, 2025
·
4 min read
Press Releases
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
March 13, 2025
·
4 min read
Press Releases
NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025
April 25, 2025
·
3 min read
Press Releases
Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)
April 2, 2025
·
2 min read
Lone Star Bio
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
Cassava Sciences, Inc., a biotechnology company focused on Alzheimer’s disease, announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distributed to its shareholders.
May 8, 2024
·
5 min read
Press Releases
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients
April 30, 2025
·
10 min read
Bio NC
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Corp. announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses.
June 10, 2024
·
5 min read
Genetown
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
TScan Therapeutics, Inc. announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock.
April 16, 2024
·
4 min read
Policy
Kanvas Biosciences Secures Additional $12.5M to Advance Its Novel, Microbiome-Based Immuno-oncology Drug Candidates to IND Filing
Kanvas Biosciences, a full-stack spatial biology company, announced it has raised $12.5 million in additional funding co-led by existing investors DCVC and Lions Capital LLC, and participation from FemHealth Ventures, Germin8, Ki Tua Fund, and Pangaea Ventures as well as existing investors.
July 1, 2024
·
6 min read
Pharm Country
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
Cencora, Inc. announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034, in an underwritten registered public offering.
February 5, 2024
·
4 min read
1 of 3,696
Next
